SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-21-027411
Filing Date
2021-11-26
Accepted
2021-11-24 20:09:45
Documents
14
Period of Report
2021-11-23
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20211124_8k.htm   iXBRL 8-K 36069
2 EXHIBIT 10.1 ex_310909.htm EX-10.1 67603
  Complete submission text file 0001437749-21-027411.txt   254734

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA navb-20211123.xsd EX-101.SCH 3595
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20211123_def.xml EX-101.DEF 11426
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20211123_lab.xml EX-101.LAB 15312
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20211123_pre.xml EX-101.PRE 11586
7 EXTRACTED XBRL INSTANCE DOCUMENT navb20211124_8k_htm.xml XML 2572
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 211448865
SIC: 2835 In Vitro & In Vivo Diagnostic Substances